PIK3CA and breast carcinoma: Although combined alpelisib and fulvestrant therapy has been approved by the FDA for the treatment of PIK3CA-mutated HR+ HER2− breast cancer, side effects, including on-target side effects such as hyperglycemia, restricted the maximum dose and thus clinical efficacy of alpelisib.